NASDAQ:XLO Xilio Therapeutics (XLO) Stock Forecast, Price & News $2.34 +0.08 (+3.54%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$1.98▼$2.3550-Day Range$2.26▼$2.9052-Week Range$1.95▼$4.92Volume20,336 shsAverage Volume28,708 shsMarket Capitalization$64.44 millionP/E RatioN/ADividend YieldN/APrice Target$11.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Xilio Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside380.8% Upside$11.25 Price TargetShort InterestHealthy0.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.81) to ($2.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector292nd out of 961 stocksPharmaceutical Preparations Industry127th out of 448 stocks 3.5 Analyst's Opinion Consensus RatingXilio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.25, Xilio Therapeutics has a forecasted upside of 380.8% from its current price of $2.34.Amount of Analyst CoverageXilio Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.39% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Xilio Therapeutics has recently decreased by 2.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XLO. Previous Next 0.6 News and Social Media Coverage Search Interest2 people have searched for XLO on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions63.49% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xilio Therapeutics are expected to grow in the coming year, from ($2.81) to ($2.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xilio Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xilio Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xilio Therapeutics (NASDAQ:XLO) StockXilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.Read More XLO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XLO Stock News HeadlinesSeptember 5, 2023 | markets.businessinsider.comXilio Therapeutics Appoints Katarina Luptakova As CMOSeptember 5, 2023 | finance.yahoo.comXilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 21, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 5, 2023 | finance.yahoo.comXilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development OfficerAugust 18, 2023 | finance.yahoo.comQ2 2023 Xilio Therapeutics Inc Earnings CallAugust 14, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comXilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating OfficerJuly 20, 2023 | uk.finance.yahoo.comXLO - Xilio Therapeutics, Inc.September 21, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 25, 2023 | finance.yahoo.comXilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid TumorsMay 12, 2023 | msn.comChardan Capital Reiterates Xilio Therapeutics (XLO) Buy RecommendationMay 10, 2023 | msn.comXilio Therapeutics GAAP EPS of -$0.83 beats by $0.06May 9, 2023 | finanznachrichten.deXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial ResultsApril 3, 2023 | finance.yahoo.comXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 2, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial ResultsFebruary 27, 2023 | finance.yahoo.comXilio Therapeutics to Present at Upcoming Investor ConferencesFebruary 16, 2023 | finance.yahoo.comXilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership SummitFebruary 2, 2023 | finance.yahoo.comXilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology DayJanuary 26, 2023 | finance.yahoo.comInstitutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the mostJanuary 25, 2023 | seekingalpha.comXLO Xilio Therapeutics, Inc.January 25, 2023 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Are on Track for Massive Gains, Say AnalystsNovember 23, 2022 | finance.yahoo.comXilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12November 9, 2022 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial ResultsSeptember 23, 2022 | finance.yahoo.comXilio Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceSeptember 6, 2022 | finance.yahoo.comXilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceAugust 11, 2022 | seekingalpha.comXilio Therapeutics GAAP EPS of -$0.90See More Headlines Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address XLO Company Calendar Last Earnings8/14/2023Today9/21/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XLO CUSIPN/A CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees84Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.25 High Stock Price Forecast$15.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+380.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.74% Return on Assets-67.35% Debt Debt-to-Equity RatioN/A Current Ratio4.81 Quick Ratio4.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.85 per share Price / Book0.61Miscellaneous Outstanding Shares27,540,000Free Float26,273,000Market Cap$64.44 million OptionableNot Optionable Beta0.25 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Rene Russo BCPS (Age 48)Pharm.D, Pharm.D., CEO & Director Comp: $888.49kDr. Martin H. Huber M.D. (Age 62)Pres and Head of R&D Comp: $740.01kMr. Kevin M. Brennan (Age 53)Sr. VP of Fin. & Accounting and Director Mr. Christopher FrankenfieldChief Operating OfficerDr. Uli Bialucha Ph.D.Chief Scientific OfficerJulissa VianaVP of Corp. CommunicationsMs. Stacey J. DavisChief Bus. OfficerMore ExecutivesKey CompetitorsVaccitechNASDAQ:VACCHomology MedicinesNASDAQ:FIXXSpero TherapeuticsNASDAQ:SPROTiziana Life SciencesNASDAQ:TLSAEliem TherapeuticsNASDAQ:ELYMView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 58,486 shares on 8/15/2023Ownership: 0.048%Charles Schwab Investment Management Inc.Bought 11,925 shares on 8/10/2023Ownership: 0.043%View All Institutional Transactions XLO Stock - Frequently Asked Questions Should I buy or sell Xilio Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares. View XLO analyst ratings or view top-rated stocks. What is Xilio Therapeutics' stock price forecast for 2023? 3 brokers have issued twelve-month price objectives for Xilio Therapeutics' shares. Their XLO share price forecasts range from $7.00 to $15.00. On average, they anticipate the company's share price to reach $11.25 in the next year. This suggests a possible upside of 380.8% from the stock's current price. View analysts price targets for XLO or view top-rated stocks among Wall Street analysts. How have XLO shares performed in 2023? Xilio Therapeutics' stock was trading at $2.69 at the start of the year. Since then, XLO shares have decreased by 13.0% and is now trading at $2.34. View the best growth stocks for 2023 here. When is Xilio Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our XLO earnings forecast. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) announced its earnings results on Monday, August, 14th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.14. When did Xilio Therapeutics IPO? (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share. What is Xilio Therapeutics' stock symbol? Xilio Therapeutics trades on the NASDAQ under the ticker symbol "XLO." Who are Xilio Therapeutics' major shareholders? Xilio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.05%) and Charles Schwab Investment Management Inc. (0.04%). Insiders that own company stock include Bain Capital Life Sciences Inv and Rock Springs Capital Managemen. View institutional ownership trends. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xilio Therapeutics' stock price today? One share of XLO stock can currently be purchased for approximately $2.34. How much money does Xilio Therapeutics make? Xilio Therapeutics (NASDAQ:XLO) has a market capitalization of $64.44 million. The company earns $-88,220,000.00 in net income (profit) each year or ($3.07) on an earnings per share basis. How can I contact Xilio Therapeutics? The official website for the company is www.xiliotx.com. The company can be reached via phone at 857-524-2466 or via email at monique@thrustsc.com. This page (NASDAQ:XLO) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.